Brief: Palatin Completes Phase 2 Obesity Study With Mc4r Bremelanotide Plus Glp-1/Gip Tirzepatide
06/02/2025 12:33
Feb 6 (Reuters) - Eli Lilly and Co LLY.N :
* PALATIN COMPLETES PHASE 2 OBESITY STUDY WITH MC4R
BREMELANOTIDE
PLUS GLP-1/GIP TIRZEPATIDE
* PALATIN TECHNOLOGIES INC - TOPLINE DATA RESULTS EXPECTED
LATER
THIS QUARTER
Source text: ID:nPnbyzcCga
Further company coverage: LLY.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palatin Technologies
See all newsPalatin Technologies Inc reports results for the quarter ended March 31 - Earnings Summary
Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Q2 revenue rises yr/yr, net loss widens
Brief: Palatin Announces 1-For-50 Reverse Stock Split
Brief: Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity